A detailed history of Charles Schwab Investment Management Inc transactions in Amgen Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 10,832,342 shares of AMGN stock, worth $3.23 Billion. This represents 0.72% of its overall portfolio holdings.

Number of Shares
10,832,342
Previous 10,393,110 4.23%
Holding current value
$3.23 Billion
Previous $2.99 Billion 2.89%
% of portfolio
0.72%
Previous 0.77%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$268.87 - $324.56 $118 Million - $143 Million
439,232 Added 4.23%
10,832,342 $3.08 Billion
Q4 2023

Feb 06, 2024

SELL
$255.7 - $288.46 $128 Million - $144 Million
-500,785 Reduced 4.6%
10,393,110 $2.99 Billion
Q3 2023

Nov 08, 2023

SELL
$218.65 - $271.46 $76.1 Million - $94.5 Million
-347,963 Reduced 3.1%
10,893,895 $2.93 Billion
Q2 2023

Aug 09, 2023

BUY
$214.27 - $253.37 $103 Million - $122 Million
480,421 Added 4.46%
11,241,858 $2.5 Billion
Q1 2023

May 11, 2023

BUY
$225.79 - $275.2 $333 Million - $406 Million
1,474,151 Added 15.87%
10,761,437 $2.6 Billion
Q4 2022

Feb 13, 2023

BUY
$229.03 - $291.01 $11.6 Million - $14.8 Million
50,756 Added 0.55%
9,287,286 $2.44 Billion
Q3 2022

Nov 14, 2022

BUY
$224.46 - $253.15 $64.6 Million - $72.9 Million
287,899 Added 3.22%
9,236,530 $2.08 Billion
Q2 2022

Aug 15, 2022

BUY
$230.71 - $256.74 $29.7 Million - $33.1 Million
128,941 Added 1.46%
8,948,631 $2.18 Billion
Q1 2022

May 13, 2022

BUY
$219.27 - $242.57 $20.7 Million - $22.9 Million
94,565 Added 1.08%
8,819,690 $2.13 Billion
Q4 2021

Feb 11, 2022

BUY
$198.88 - $227.6 $112 Million - $128 Million
561,955 Added 6.88%
8,725,125 $1.96 Billion
Q3 2021

Nov 16, 2021

BUY
$212.27 - $248.7 $196 Million - $229 Million
921,133 Added 12.72%
8,163,170 $1.74 Billion
Q2 2021

Aug 16, 2021

BUY
$233.58 - $259.14 $204 Million - $226 Million
871,428 Added 13.68%
7,242,037 $1.77 Billion
Q1 2021

May 17, 2021

BUY
$221.91 - $258.6 $797 Million - $929 Million
3,591,016 Added 129.19%
6,370,609 $1.59 Billion
Q4 2020

Feb 16, 2021

BUY
$216.38 - $257.67 $5.02 Million - $5.98 Million
23,212 Added 0.84%
2,779,593 $639 Million
Q3 2020

Nov 13, 2020

SELL
$234.65 - $260.95 $10.4 Million - $11.6 Million
-44,454 Reduced 1.59%
2,756,381 $701 Million
Q2 2020

Aug 14, 2020

SELL
$197.81 - $242.74 $10.6 Million - $13 Million
-53,551 Reduced 1.88%
2,800,835 $661 Million
Q1 2020

May 15, 2020

BUY
$182.24 - $241.7 $9.02 Million - $12 Million
49,496 Added 1.76%
2,854,386 $579 Million
Q4 2019

Feb 07, 2020

SELL
$189.21 - $243.2 $12.4 Million - $15.9 Million
-65,428 Reduced 2.28%
2,804,890 $676 Million
Q3 2019

Nov 08, 2019

SELL
$174.11 - $208.62 $22.2 Million - $26.6 Million
-127,397 Reduced 4.25%
2,870,318 $555 Million
Q2 2019

Aug 09, 2019

SELL
$166.7 - $195.41 $7.75 Million - $9.08 Million
-46,466 Reduced 1.53%
2,997,715 $552 Million
Q1 2019

May 14, 2019

SELL
$180.87 - $203.88 $9.16 Million - $10.3 Million
-50,639 Reduced 1.64%
3,044,181 $578 Million
Q4 2018

Feb 14, 2019

SELL
$178.4 - $208.25 $6.33 Million - $7.39 Million
-35,501 Reduced 1.13%
3,094,820 $602 Million
Q3 2018

Nov 13, 2018

SELL
$185.29 - $208.89 $14.3 Million - $16.1 Million
-76,921 Reduced 2.4%
3,130,321 $649 Million
Q2 2018

Aug 08, 2018

BUY
$166.05 - $186.51 $12 Million - $13.5 Million
72,205 Added 2.3%
3,207,242 $592 Million
Q1 2018

May 07, 2018

SELL
$169.43 - $198.0 $28.7 Million - $33.5 Million
-169,303 Reduced 5.12%
3,135,037 $534 Million
Q4 2017

Jan 17, 2018

BUY
$168.79 - $188.59 $20.8 Million - $23.2 Million
123,250 Added 3.87%
3,304,340 $575 Million
Q3 2017

Nov 13, 2017

BUY
$167.29 - $191.0 $532 Million - $608 Million
3,181,090
3,181,090 $593 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $160B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.